Fig. 1: Overall survival, event-free survival, response rates, and response duration for study population and disease subgroups. | Leukemia

Fig. 1: Overall survival, event-free survival, response rates, and response duration for study population and disease subgroups.

From: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML

Fig. 1

a OS in the ITT population. b EFS in the ITT population. c OS in higher-risk MDS. d EFS in higher-risk MDS. e Response rate and duration of response in higher-risk MDS (f) OS in LB-AML. g OS in higher-risk CMML; h EFS in higher-risk CMML. CI confidence interval, CR complete remission, EFS event-free survival, HI hematologic improvement, ITT intent-to-treat, LB-AML low-blast AML, MDS myelodysplastic syndromes, NE not evaluable, ORR objective response rate, OS overall survival, PR partial response.

Back to article page